Hideki Koizumi

Okinawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 115 publications

Protocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial.

Protocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial.

Journal: PloS one

Published: June 05, 2026

Anterior scleral thickness in eyes with central serous chorioretinopathy: A systematic review and meta-analysis.

Anterior scleral thickness in eyes with central serous chorioretinopathy: A systematic review and meta-analysis.

Journal: Acta ophthalmologica

Published: April 30, 2026

Central Serous Chorioretinopathy in patients with preexisting immune-mediated disorders: MICRoN report 21.

Central Serous Chorioretinopathy in patients with preexisting immune-mediated disorders: MICRoN report 21.

Journal: American journal of ophthalmology

Published: April 17, 2026

Mapping Resident Perspectives on Safety, Participation, and Security Devices: Insights into Community Security Governance in Urban China.

Mapping Resident Perspectives on Safety, Participation, and Security Devices: Insights into Community Security Governance in Urban China.

Journal: International journal of offender therapy and comparative criminology

Published: April 14, 2026

Predictors of Good Visual Recovery in Patients With Spontaneously Resolved Acute CSCR - MICRoN Report Number Thirteen.

Predictors of Good Visual Recovery in Patients With Spontaneously Resolved Acute CSCR - MICRoN Report Number Thirteen.

Journal: American journal of ophthalmology

Published: March 13, 2026

Predictors of Good Visual Recovery in Patients with Spontaneously Resolved Acute CSCR - MICRoN Report Number Thirteen.

Predictors of Good Visual Recovery in Patients with Spontaneously Resolved Acute CSCR - MICRoN Report Number Thirteen.

Journal: American journal of ophthalmology

Published: March 13, 2026

Six-month outcomes with a reduced two-injection induction (2+TAE) regimen of aflibercept 8 mg in treatment-naive neovascular age-related macular degeneration.

Six-month outcomes with a reduced two-injection induction (2+TAE) regimen of aflibercept 8 mg in treatment-naive neovascular age-related macular degeneration.

Journal: Japanese journal of ophthalmology

Published: February 09, 2026

Evaluation of Melanin Changes in Acute Vogt-Koyanagi-Harada Disease Using Polarization-Sensitive Optical Coherence Tomography.

Evaluation of Melanin Changes in Acute Vogt-Koyanagi-Harada Disease Using Polarization-Sensitive Optical Coherence Tomography.

Journal: Investigative ophthalmology & visual science

Published: January 14, 2026

CHANGES IN WIDEFIELD CHOROIDAL THICKNESS AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

CHANGES IN WIDEFIELD CHOROIDAL THICKNESS AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Journal: Retina (Philadelphia, Pa.)

Published: September 02, 2025

Impact of Reticular Pseudodrusen on Clinical and Ocular Characteristics and Progression Rate of Geographic Atrophy in Japanese Patients.

Impact of Reticular Pseudodrusen on Clinical and Ocular Characteristics and Progression Rate of Geographic Atrophy in Japanese Patients.

Journal: Ophthalmology science

Published: May 21, 2025

International consensuses and guidelines on central serous chorioretinopathy (CSC) by the Asia Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI).

International consensuses and guidelines on central serous chorioretinopathy (CSC) by the Asia Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI).

Journal: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)

Published: May 15, 2025

Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration.

Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration.

Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Published: May 14, 2025

Showing 1-12 of 115

Last Updated: 09/26/2026